公开(公告)号：US20240382605A1

公开(公告)日：2024-11-21

申请号：US18696199

申请日：2022-09-29

Applicant: Ionis Pharmaceuticals, Inc. ,  BicycleTx Limited

Inventor： Punit P. Seth ,  Michael Oestergaard ,  Michele Carrer ,  Michael Tanowitz ,  Michael Rigby ,  Michael Skynner ,  Steven Stanway ,  Liudvikas Urbonas ,  Katerine Van Rietschoten

IPC: A61K47/64 ,  A61K9/00 ,  A61P21/00 ,  C12N15/113

Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.

公开(公告)号：US11970555B2

公开(公告)日：2024-04-30

申请号：US17454665

申请日：2021-11-12

Applicant: BicycleTx Limited

Inventor： Ellen Gowans ,  Gemma Elizabeth Mudd ,  Michael Rigby ,  Punit Seth ,  Michael Skynner ,  Steven Stanway ,  Liudvikas Urbonas ,  Katerine Van Rietschoten

IPC: C07K7/64 ,  A61K47/55 ,  A61K47/64 ,  C07K1/107

CPC classification number: C07K7/64 ,  A61K47/55 ,  A61K47/64 ,  C07K1/1075

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

公开(公告)号：US20240091368A1

公开(公告)日：2024-03-21

申请号：US18271340

申请日：2022-01-10

Applicant: BICYCLETX LIMITED

Inventor： Nicholas KEEN ,  Katerine VAN RIETSCHOTEN ,  Liuhong CHEN ,  Maximilian HARMAN ,  Paul BESWICK ,  Paul BESWICK

IPC: A61K47/60 ,  A61K47/64

CPC classification number: A61K47/60 ,  A61K47/641

Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.

公开(公告)号：US20230144799A1

公开(公告)日：2023-05-11

申请号：US17934896

申请日：2022-09-23

Applicant: BicycleTx Limited

Inventor： Liuhong CHEN ,  Philip HUXLEY ,  Silvia Pavan ,  Katerine Van Rietschoten

IPC: A61K47/64 ,  A61P35/00 ,  A61K47/65 ,  A61K38/10 ,  A61K38/05 ,  A61K47/62 ,  C07K7/08

CPC classification number: A61K47/6415 ,  A61P35/00 ,  A61K47/65 ,  A61K38/10 ,  A61K38/05 ,  A61K47/62 ,  C07K7/08 ,  A61K47/64

Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

公开(公告)号：US20220363718A1

公开(公告)日：2022-11-17

申请号：US17223244

申请日：2021-04-06

Applicant: BicycleTx Limited

Inventor： Frank NARJES ,  Tor SVENSSON ,  Pavol ZLATOIDSKY ,  Lotta HIDESTAL ,  Liuhong CHEN ,  Michael SKYNNER ,  Sophie WATCHAM

IPC: C07K7/64 ,  A61K47/54

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.

公开(公告)号：US20220362390A1

公开(公告)日：2022-11-17

申请号：US17309631

申请日：2019-12-13

Applicant: BicycleTx Limited

Inventor： Catherine STACE ,  Daniel TEUFEL ,  Edward WALKER

IPC: A61K47/64 ,  A61K47/55 ,  C07K7/64

Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site of MT1-MMP. The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.

公开(公告)号：US20220306689A9

公开(公告)日：2022-09-29

申请号：US17044868

申请日：2019-12-23

Applicant: BicycleTx Limited

Inventor： Liuhong CHEN ,  James COOKE ,  Kevin MCDONNELL ,  Gemma MUDD ,  Katerine VAN RIETSCHOTEN ,  Punit UPADHYAYA

IPC: C07K7/08 ,  A61K47/64

Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

公开(公告)号：US20220184222A1

公开(公告)日：2022-06-16

申请号：US17594031

申请日：2020-04-02

Applicant: BicycleTx Limited

Inventor： Gavin BENNETT ,  Johanna LAHDENRANTA

IPC: A61K47/64 ,  A61P35/00 ,  A61K47/65

Abstract: The present invention relates to Bicycle toxin conjugates, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof for preventing or treating a disease, disorder, or condition characterised by overexpression of EphA2 in diseased tissue, such as cancer.

公开(公告)号：US11306123B2

公开(公告)日：2022-04-19

申请号：US16941614

申请日：2020-07-29

Applicant: BicycleTx Limited

Inventor： Gemma Mudd ,  Punit Upadhyaya ,  Kevin McDonnell ,  Johanna Lahdenranta

IPC: C07K7/08 ,  A61K38/00 ,  A61P35/00 ,  A61K9/00 ,  A61K38/12

Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

公开(公告)号：US20220088207A1

公开(公告)日：2022-03-24

申请号：US17416562

申请日：2019-12-23

Applicant: BicycleTx Limited

Inventor： Liuhong CHEN ,  James COOKE ,  Kevin MCDONNELL ,  Gemma MUDD ,  Katerine VAN RIETSCHOTEN ,  Punit UPADHYAYA

IPC: A61K47/64 ,  C07K7/64

Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.